Supernus Pharmaceuticals (NASDAQ:SUPN) Hits New 12-Month Low – What’s Next?

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) reached a new 52-week low during trading on Tuesday . The company traded as low as $42.39 and last traded at $42.42, with a volume of 129584 shares. The stock had previously closed at $43.53.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on SUPN shares. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a report on Wednesday, June 24th. Wall Street Zen downgraded shares of Supernus Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, August 8th. Zacks Research upgraded shares of Supernus Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Thursday, August 6th. Finally, Cantor Fitzgerald raised their target price on shares of Supernus Pharmaceuticals from $63.00 to $67.00 and gave the company an “overweight” rating in a research note on Thursday, July 9th. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Supernus Pharmaceuticals has an average rating of “Moderate Buy” and a consensus target price of $62.83.

Supernus Pharmaceuticals Stock Down 2.5%

The company’s 50 day moving average price is $46.62 and its two-hundred day moving average price is $48.34. The firm has a market cap of $2.47 billion, a PE ratio of -22.10, a P/E/G ratio of 0.80 and a beta of 0.56.

Supernus Pharmaceuticals (NASDAQ:SUPN) last released its quarterly earnings results on Monday, August 3rd. The specialty pharmaceutical company reported ($1.01) EPS for the quarter, missing analysts’ consensus estimates of $0.42 by ($1.43). The firm had revenue of $219.06 million for the quarter, compared to analysts’ expectations of $205.31 million. Supernus Pharmaceuticals had a positive return on equity of 11.13% and a negative net margin of 13.23%.Supernus Pharmaceuticals’s revenue for the quarter was up 32.4% on a year-over-year basis. During the same period in the prior year, the firm posted $0.40 earnings per share. On average, analysts expect that Supernus Pharmaceuticals, Inc. will post 1.97 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the business. Sit Investment Associates Inc. grew its stake in shares of Supernus Pharmaceuticals by 0.4% during the fourth quarter. Sit Investment Associates Inc. now owns 65,200 shares of the specialty pharmaceutical company’s stock valued at $3,240,000 after buying an additional 250 shares during the last quarter. Summit Global Investments boosted its holdings in Supernus Pharmaceuticals by 6.1% during the 1st quarter. Summit Global Investments now owns 4,436 shares of the specialty pharmaceutical company’s stock valued at $229,000 after acquiring an additional 256 shares during the period. Maryland State Retirement & Pension System grew its position in Supernus Pharmaceuticals by 3.6% in the 4th quarter. Maryland State Retirement & Pension System now owns 8,351 shares of the specialty pharmaceutical company’s stock valued at $415,000 after acquiring an additional 290 shares during the last quarter. SummitTX Capital L.P. increased its stake in Supernus Pharmaceuticals by 2.7% in the fourth quarter. SummitTX Capital L.P. now owns 11,670 shares of the specialty pharmaceutical company’s stock worth $580,000 after purchasing an additional 303 shares during the period. Finally, PNC Financial Services Group Inc. increased its stake in Supernus Pharmaceuticals by 2.3% in the first quarter. PNC Financial Services Group Inc. now owns 14,548 shares of the specialty pharmaceutical company’s stock worth $752,000 after purchasing an additional 321 shares during the period.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.